XML 97 R87.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment Data (Schedule of Net Sales from External Customers by Products) (Details) - USD ($)
$ in Millions
3 Months Ended
Dec. 25, 2015
Dec. 26, 2014
Segment Reporting Information [Line Items]    
Net sales $ 914.8 $ 768.2
Operating Segments    
Segment Reporting Information [Line Items]    
Net sales 904.4 759.7
Operating Segments | Specialty Brands    
Segment Reporting Information [Line Items]    
Net sales 543.2 373.6
Operating Segments | Specialty Generics    
Segment Reporting Information [Line Items]    
Net sales 257.6 284.2
Operating Segments | Nuclear Imaging    
Segment Reporting Information [Line Items]    
Net sales 103.6 101.9
Corporate, Non-Segment    
Segment Reporting Information [Line Items]    
Net sales [1] 10.4 8.5
H. P. Acthar Gel | Operating Segments | Specialty Brands    
Segment Reporting Information [Line Items]    
Net sales 286.7 266.4
Ofirmev | Operating Segments | Specialty Brands    
Segment Reporting Information [Line Items]    
Net sales 66.9 71.4
Therakos | Operating Segments | Specialty Brands    
Segment Reporting Information [Line Items]    
Net sales 50.4 0.0
Inomax | Operating Segments | Specialty Brands    
Segment Reporting Information [Line Items]    
Net sales 110.8 0.0
Other | Operating Segments | Specialty Brands    
Segment Reporting Information [Line Items]    
Net sales 28.4 35.8
Other | Operating Segments | Specialty Generics    
Segment Reporting Information [Line Items]    
Net sales 51.1 42.7
Oxycodone (API) | Operating Segments | Specialty Generics    
Segment Reporting Information [Line Items]    
Net sales 28.9 47.0
Hydrocodone (API) | Operating Segments | Specialty Generics    
Segment Reporting Information [Line Items]    
Net sales 36.7 34.0
Methylphenidate ER (Specialty Generics) | Operating Segments | Specialty Generics    
Segment Reporting Information [Line Items]    
Net sales 31.2 48.6
Other Controlled Substances | Operating Segments | Specialty Generics    
Segment Reporting Information [Line Items]    
Net sales $ 109.7 $ 111.9
[1] Represents historical CMDS-related intercompany transactions that represent Mallinckrodt continuing operations under an ongoing supply agreement with the acquirer of the CMDS business.